US HBW Business News: OTC Migraine Treatment Device Cleared, Nestle Closes Aimmune Deal, More
Cefaly touts first OTC dual-Purpose eTNS migraine device available in US; Nestle Health Science closes on its acquisition of Aimmune Therapeutics; Elderberry supplement marketer Matherson Organics complies with NAD recommendations rather than face FTC scrutiny; and nutrition product firm Vidafuel closes on $1.6m financing round.
You may also be interested in...
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
The National Advertising Division says it will refer Matherson Organics to regulators for possible enforcement after it failed to provide a substantive response to an inquiry on an Instagram claim that suggested Vitamin Bounty Elderberry Immune Support could help prevent or treat COVID-19.
Boston coalition offers pro-bono legal help for small businesses, nonprofits; CBD firms Neptune Wellness Solutions and cbdMD respond to loosened US prohibitions for preparing sanitizers; Modere supplements provides first responders with free products; Young Living donates sanitizer in community; VidaFuel Nutition provides protein drinks to vulnerable kidney patients.